CN1747726A - A therapeutic composition for the treatment of hiv-1 and hiv-2 - Google Patents
A therapeutic composition for the treatment of hiv-1 and hiv-2 Download PDFInfo
- Publication number
- CN1747726A CN1747726A CNA2004800039434A CN200480003943A CN1747726A CN 1747726 A CN1747726 A CN 1747726A CN A2004800039434 A CNA2004800039434 A CN A2004800039434A CN 200480003943 A CN200480003943 A CN 200480003943A CN 1747726 A CN1747726 A CN 1747726A
- Authority
- CN
- China
- Prior art keywords
- content
- arrives
- tetraazaheptaeicosane
- acetylhydroxylamino
- inuline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A pharmaceutical mixture and a method of its production of a therapeutic composition for blocking the HIV-1 and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS for the treatment of HIV in a patient in need of such treatment.
Description
The applicant requires the U.S. Patent application No.10/353 with proposition on January 29th, 2003, and 48 is priority.
Technical field
The present invention relates to can be used for the technical field of the antibiotic property material of food preservation etc., especially about new lactic bacteria strain and the new antibiotic property peptide that utilizes this bacterial strain to produce.
Background technology
A kind of at HIV-1 and/or HIV-2 viral infection all stages and acquired immune deficiency syndrome (AIDS) in the medicinal mixture of blocking-up HIV-1 and/or the virus replication of HIV-2 in the CD4+ of human immunity system cell, and the method for the medicinal mixture that in the CD4+ of human immunity system cell, duplicates of a kind of preparation blocking-up HIV-1 and/or HIV-2 virus in all stages of HIV-1 and/or HIV-2 viral infection and acquired immune deficiency syndrome (AIDS).
Term " HIV treatment " and " needing the patient's of this treatment HIV treatment " should be understood to treat the patient who carries HIV-1 and/or HIV-2 hereinafter.And the meaning of term " blocking-up HIV virus replication " is blocking-up HIV-1 and/or HIV-2 virus replication.Further, term " HIV virus " is meant HIV-1 and/or HIV-2 virus.Further, term " HIV viral infection " is meant HIV-1 and/or HIV-2 viral infection.
Theme of the present invention be a kind of at HIV-1 and/or HIV-2 viral infection all stages and acquired immune deficiency syndrome (AIDS) in the medicinal mixture of blocking-up HIV-1 and/or the virus replication of HIV-2 in the CD4+ of human immunity system cell, and the method for a kind of preparation medicinal mixture of blocking-up HIV-1 and/or the virus replication of HIV-2 in the CD4+ of human immunity system cell in all stages of HIV-1 and/or HIV-2 viral infection and acquired immune deficiency syndrome (AIDS).
This inventive compositions has unique application in the treatment of acquired immune deficiency syndrome (AIDS) or acquired immune deficiency syndrome (AIDS).
Summary of the invention
Theme of the present invention be a kind of at HIV-1 and/or HIV-2 viral infection all stages and acquired immune deficiency syndrome (AIDS) in the medicinal mixture of blocking-up HIV-1 and/or the virus replication of HIV-2 in the CD4+ of human immunity system cell, known carrier and/or complementary material before it comprises, and active substance, and, it is characterized in that containing at least 10 kinds of chemical substances as active substance, wherein the content of allocryptopine is that 1.0mg is to 10.0mg, the content of nimodipine is that 20.0mg is to 100.0mg, the content of potassium iodide is that 120.0mg is to 560.0mg, the content of potassium iodate is 30.0mg to 140.0mg, and the content of inuline is that 125.0mg is to 375.0mg; , silver content be 0.10mg to 0.50mg, the content of zinc be 10.0mg to 20.0mg, the content of chromium be 0.05mg to 0.20mg, the content of orotic acid be 150.0mg to 500.0mg, the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane (desferrin) is that 100.0mg is to 300.0mg.
The specific embodiment
A kind of medicinal mixture and a kind of method for preparing this therapeutic composition, this therapeutic composition is blocking-up HIV-1 and/or the virus replication of HIV-2 in the CD4+ of human immunity system cell in all stages that HIV-1 and/or HIV-2 infect and acquired immune deficiency syndrome (AIDS), be used for the HIV treatment of the HIV sufferers of this treatment of needs, this therapeutic composition comprises allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, the 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane with knock-down.In one embodiment of the invention, this medicinal mixture further comprises taraxasterol and the B-sitosterol with knock-down.
The invention still further relates to the method for a kind of preparation medicinal mixture of blocking-up HIV-1 and/or the virus replication of HIV-2 in the CD4+ of human immunity system cell in all stages of HIV-1 and/or HIV-2 viral infection and acquired immune deficiency syndrome (AIDS), it is characterized in that, at room temperature mix following compounds until obtaining a kind of almost uniform mixture: allocryptopine 1.0mg is to 10.0mg, nimodipine 20.0mg is to 100.0mg, potassium iodide 120.0mg is to 560.0mg, potassium iodate 30.0mg is to 140.0mg, inuline 125.0mg is to 375.0mg, silver 0.10mg is to 0.50mg, zinc 10.0mg is to 20.0mg, chromium 0.05mg is to 0.20mg, orotic acid 150.0mg is to 500.0mg, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane 100.0mg is to 300.0mg, next, can be pressed into tablet, also can make a kind of tablet with coating, perhaps also can make wafer (wafer), suppository, effervescent powder, gel or colloid solution are perhaps made suspension, syrup, dissolve in the salt of body fluid or intramuscular injection or intravenous injection liquid, also can be contained in the ampoule bottle.
Existing relevant treatment be diagnosed as that HIV infects or the publication of the patient's of acquired immune deficiency syndrome (AIDS) (acquired immune deficiency syndrome (AIDS)) method in, all do not described anyly here, blocked the Drug therapy/pharmaceutical preparation of HIV-1 and/or the HIV-2 virus replication in the CD4+ of human immunity system cell based on the reasoning of being adopted.
Prerequisite of the present invention in this discussion is following reasoning, that is, the basis of HIV-1 and the HIV-2 virus replication in the CD4+ of human immunity system cell is to be that exeitono-excimeric is relevant between HIV-1 and HIV-2 virus and the CD4+ of the human immunity system cell.
Adopt the result of this reasoning as follows: the beginning that is intended to treat the therapy of HIV-1 and HIV-2 viral infection and acquired immune deficiency syndrome (AIDS) just be reduced to make the approach that duplicates of blocking HIV-1 and HIV-2 virus fully species distribution in the patient body.
It is helpful that following material has been proved finishing this task: allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane.Other material that helps to finish this task of having found has: taraxasterol and B-sitosterol.
Know, allocryptopine is a kind of nucleotide phosphodiesterase blocker, nimodipine is a kind of calcium channel blocker, under acid condition, unite and use potassium iodide and potassium iodate can produce the iodine free radical, inuline is a kind of polysaccharide of not degrading in vivo, silver, zinc and chromium are the elements that plays a role in the enzyme catalysis process, and 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane chelated iron ion, orotic acid are a kind of precursors of nucleotide compound.
Yet material listed above never occurred together in the past or used, and especially never used together in treatment for example described in the invention is used.
An object of the present invention is to provide a kind of medicinal mixture that is used for blocking HIV1 and HIV-2 virus replication in the CD4+ of the human immunity system cell.
The invention provides a kind of at HIV-1 and/or HIV-2 viral infection all stages and acquired immune deficiency syndrome (AIDS) in the medicinal mixture of blocking-up HIV-1 and/or the virus replication of HIV-2 in the CD4+ of human immunity system cell, known carrier and/or complementary material before it comprises, and active substance, it is characterized in that containing at least 10 kinds of chemical substances as active substance, wherein:
The content of-allocryptopine be 1.0mg to 10.0mg,
The content of-nimodipine be 20.0mg to 100.0mg,
The content of-potassium iodide be 120.0mg to 560.0mg,
The content of-potassium iodate is 30.0mg to 140.0mg,
The content of-inuline be 125.0mg to 375.0mg,
The content of-Yin be 0.10mg to 0.50mg,
The content of-zinc be 10.0mg to 20.0mg,
The content of-chromium be 0.05mg to 0.20mg,
The content of-orotic acid be 150.0mg to 500.0mg,
The content of-1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is that 100.0mg is to 300.0mg.
Following proportioning helps achieving the goal:
The content of allocryptopine is 10.0mg, the content of nimodipine is 100.0mg, the content of potassium iodide is 560.0mg, the content of potassium iodate is 140.0mg, and the content of inuline is 375.0mg, and the content of silver is 0.50mg, the content of zinc is 20.0mg, the content of chromium is 0.20mg, and the content of orotic acid is 500.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is 300.0mg.
Be preferably as follows proportioning:
The content of allocryptopine is 4.50mg, the content of nimodipine is 60.0mg, the content of potassium iodide is 340.0mg, the content of potassium iodate is 85.0mg, and the content of inuline is 250.0mg, and the content of silver is 0.30mg, the content of zinc is 15.0mg, the content of chromium is 0.125mg, and the content of orotic acid is 325.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is 200.0mg.
Be preferably as follows proportioning:
The content of allocryptopine is 4.50mg, the content of nimodipine is 60.0mg, and the content of potassium iodide is 340.0mg, and the content of potassium iodate is 85.0mg, the content of inuline is 250.0mg, the content of silver is 0.30mg, and the content of zinc is 15.0mg, and the content of chromium is 0.125mg, the content of orotic acid is 325.0mg, the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is 200.0mg, and the content of taraxasterol is 350mg, and the content of B-sitosterol is 400mg.
Be preferably as follows proportioning:
The content of allocryptopine is 1.0mg, the content of nimodipine is 20.0mg, and the content of potassium iodide is 120.0mg, and the content of potassium iodate is 30.0mg, the content of inuline is 125.0mg, the content of silver is 0.10mg, and the content of zinc is 10.0mg, and the content of chromium is 0.05mg, the content of orotic acid is 250.0mg, the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is 100.0mg, and the content of taraxasterol is 250mg, and the content of B-sitosterol is 300mg.
Be preferably as follows proportioning:
The content of allocryptopine is 1.0mg, the content of nimodipine is 20.0mg, the content of potassium iodide is 120.0mg, the content of potassium iodate is 30.0mg, and the content of inuline is 125.0mg, and the content of silver is 0.10mg, the content of zinc is 10.0mg, the content of chromium is 0.05mg, and the content of orotic acid is 250.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is 100.0mg
Preferred allocryptopine: nimodipine: potassium iodide: potassium iodate: inuline: silver: zinc: chromium: orotic acid: 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane in weight ratio, remained on 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250: 100.
The mixture of these compositions is preferably tablet, has the tablet of coating, wafer, suppository, effervescent powder, gel or colloid solution.
These mixture of ingredients are preferably suspension, syrup or dissolve in the salt of body fluid, intramuscular injection liquid or intravenous injection liquid.
The method of a kind of preparation medicinal mixture of blocking-up HIV-1 and/or the virus replication of HIV-2 in the CD4+ of human immunity system cell in all stages of HIV-1 and/or HIV-2 viral infection and acquired immune deficiency syndrome (AIDS), it is characterized in that, at room temperature mix following ingredients to obtaining the homogeneous mixture:
The content of-allocryptopine be 1.0mg to 10.0mg,
The content of-nimodipine be 20.0mg to 100.0mg,
The content of-potassium iodide be 120.0mg to 560.0mg,
The content of-potassium iodate is 30.0mg to 140.0mg,
The content of-inuline be 125.0mg to 375.0mg,
The content of-Yin be 0.10mg to 0.50mg,
The content of-zinc be 10.0mg to 20.0mg,
The content of-chromium be 0.05mg to 0.20mg,
The content of-orotic acid be 150.0mg to 500.0mg,
The content of-1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is that 100.0mg is to 300.0mg.
Be preferably as follows proportioning:
The content of allocryptopine is 10.0mg, the content of nimodipine is 100.0mg, the content of potassium iodide is 560.0mg, the content of potassium iodate is 140.0mg, and the content of inuline is 375.0mg, and the content of silver is 0.50mg, the content of zinc is 20.0mg, the content of chromium is 0.20mg, and the content of orotic acid is 500.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is 300.0mg.
Be preferably as follows proportioning:
The content of allocryptopine is 4.50mg, the content of nimodipine is 60.0mg, the content of potassium iodide is 340.0mg, the content of potassium iodate is 85.0mg, and the content of inuline is 250.0mg, and the content of silver is 0.30mg, the content of zinc is 15.0mg, the content of chromium is 0.125mg, and the content of orotic acid is 325.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is 200.0mg.
Be preferably as follows proportioning:
The content of allocryptopine is 1.0mg, the content of nimodipine is 20.0mg, the content of potassium iodide is 120.0mg, the content of potassium iodate is 30.0mg, and the content of inuline is 125.0mg, and the content of silver is 0.10mg, the content of zinc is 10.0mg, the content of chromium is 0.05mg, and the content of orotic acid is 250.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is 100.0mg.
Preferred allocryptopine: nimodipine: potassium iodide: potassium iodate: inuline: silver: zinc: chromium: orotic acid: 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane by quality ratio, remained on 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250: 100.
The method of said medicine mixture and this medicinal mixture of preparation can further comprise taraxasterol and the B-sitosterol with knock-down.Preferred said medicine mixture and preparation method thereof is characterised in that, at room temperature following material is mixed until the mixture that obtains a kind of almost homogeneous: allocryptopine 1.0mg is to 10.0mg, nimodipine 20.0mg is to 100.0mg, potassium iodide 120.0mg is to 560.0mg, potassium iodate 30.0mg to 140.0mg, inuline 125.0mg is to 375.0mg, silver 0.10mg is to 0.50mg, zinc 10.0mg is to 20.0mg, chromium 0.05mg is to 0.20mg, orotic acid 150.0mg is to 500.0mg, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane, 100.0mg to 300.0mg, taraxasterol 250mg is to 400mg, with B-sitosterol 300mg to 500mg, next, can be pressed into tablet, also can make tablet with coating, perhaps also can make wafer, suppository, effervescent powder, gel or colloid solution, perhaps make suspension, syrup, dissolve in body fluid, intramuscular injection liquid, or the salt of intravenous injection liquid, also can be contained in the ampoule bottle.
Preferred allocryptopine: nimodipine: potassium iodide: potassium iodate: inuline: silver: zinc: chromium: orotic acid: 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane: taraxasterol: the B-sitosterol in weight ratio, remained on 1: 20: 120: 30: 125; 0.1: 10: 0.05: 250: 100: 400: 500.
Preferred allocryptopine: nimodipine: potassium iodide: potassium iodate: inuline: silver: zinc: chromium: orotic acid: 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane: taraxasterol: B-sitosterol, in weight ratio, remained on 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250: 100: 350: 400.
These mixture of ingredients are preferably tablet, have the tablet of coating, wafer, suppository, effervescent powder, gel, perhaps colloid solution.
These mixture of ingredients are preferably suspension, syrup or dissolve in the salt of body fluid, intramuscular injection liquid or intravenous injection liquid.
The favourable function of the medicinal mixture among the present invention is the approach of receptors bind on gp160 albumen and the CD4+ of the human immunity system cell of blocking-up HIV capsule, and the while has also been blocked the cell internal procedure relevant with the HIV-2 virus replication with HIV-1.
Example 1: the composition of medicinal mixture:
Allocryptopine 10.0mg, nimodipine 100.0mg, potassium iodide 560.0mg, potassium iodate 140.0mg, inuline 375.0mg, silver-colored 0.50mg, zinc 20.0mg, chromium 0.20mg, orotic acid 500.0mg, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane 300.0mg.
The preparation of medicinal mixture:
Following material is at room temperature mixed: 10.0mg allocryptopine, 100.0mg nimodipine, 560.0mg potassium iodide, 140.0mg potassium iodate, 375.0mg inuline, 0.50mg silver, 20.0mg zinc, 0.20mg chromium, 500.0mg orotic acid, 300.0mg 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane.
After adding all the components, they are mixed together 10-20 minute until becoming the homogeneous mixture.Next this mixture can be pressed into tablet, also can be the tablet with coating, perhaps wafer, suppository, effervescent powder, gel, perhaps colloid solution.
Example 2: the composition of medicinal mixture:
Allocryptopine 1.0mg, nimodipine 20.0mg, potassium iodide 120.0mg, potassium iodate 30.0mg, inuline 125.0mg, silver-colored 0.10mg, zinc 10.0mg, chromium 0.05mg, orotic acid 150.0mg, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane 100.0mg.
The preparation of medicinal mixture:
Following material is at room temperature mixed: 1.0mg allocryptopine, 20.0mg nimodipine, 120.0mg potassium iodide, 30.0mg potassium iodate, 125.0mg inuline, 0.10mg silver, 10.0mg zinc, 0.05mg chromium, 150.0mg orotic acid, 100.0g 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane.
After adding all the components, they are mixed together 10-20 minute until becoming the homogeneous mixture.Next this mixture can be made into suspension, and syrup dissolves in the salt of body fluid or intramuscular injection liquid or intravenous injection liquid, also can be contained in the ampoule bottle.
Example 3: the composition of medicinal mixture:
Allocryptopine 10.0mg, nimodipine 100.0mg, potassium iodide 560.0mg, potassium iodate 140.0mg, inuline 375.0mg, silver-colored 0.50mg, zinc 20.0mg, chromium 0.20mg, orotic acid 500.0mg, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane 300.0mg, taraxasterol 400mg, B-sitosterol 500mg.
The preparation of medicinal mixture:
Following material is at room temperature mixed: 10.0mg allocryptopine, 100.0mg nimodipine, 560.0mg potassium iodide, 140.0mg potassium iodate, 375.0mg inuline, 0.50mg silver, 20.0mg zinc, 0.20mg chromium, 500.0mg orotic acid, 300.0mg 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane, 400mg taraxasterol, 500mgB-sitosterol.
After adding all the components, they are mixed together 10-20 minute until becoming the homogeneous mixture.Next this mixture can be pressed into tablet, also can be the tablet with coating, perhaps wafer, suppository, effervescent powder, gel, perhaps colloid solution.
Example 4: the composition of medicinal mixture:
Allocryptopine 1.0mg, nimodipine 20.0mg, potassium iodide 120.0mg, potassium iodate 30.0mg, inuline 125.0mg, silver-colored 0.10mg, zinc 10.0mg, chromium 0.05mg, orotic acid 150.0mg, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane 100.0mg, taraxasterol 250mg, B-sitosterol 300mg.
The preparation of medicinal mixture:
Following material is at room temperature mixed: 1.0mg allocryptopine, 20.0mg nimodipine, 120.0mg potassium iodide, 30.0mg potassium iodate, 125.0mg inuline, 0.10mg silver, 10.0mg zinc, 0.05mg chromium, 150.0mg orotic acid, 100.0mg 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane, 250mg taraxasterol, 300mgB-sitosterol.
After adding all the components, they are mixed together 10-20 minute until becoming the homogeneous mixture.Next this mixture can be made into suspension, and syrup dissolves in the salt of body fluid or intramuscular injection liquid or intravenous injection liquid, also can be contained in the ampoule bottle.
Term " has knock-down " and is meant the effective dose of Chinese medicine mixture of the present invention (mixture that comprises allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane).The actual dose of medicinal mixture of the present invention for particular patient, composition and administering mode, can change to some extent to reach satisfied curative effect.Selected dosage depends on the activity of specific compound, route of administration, the patient's who is treated the state of an illness and health and former medication history.Yet from beginning progressively to improve dosage than reaching the low dosage of expectation curative effect required compound, until reaching desired effect, this is also included within the skill of this area.
Claims (31)
1. therapeutic composition that is used for the treatment of the patient's who needs HIV treatment HIV, this therapeutic composition comprises: allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane.
2. the therapeutic composition described in the claim 1, wherein, the content of allocryptopine arrives about 10.0mg for about 1.0mg, the content of nimodipine arrives about 100.0mg for about 20.0mg, the content of potassium iodide arrives about 560.0mg for about 120.0mg, the content of potassium iodate arrives about 140.0mg for about 30.0mg, the content of inuline arrives about 375.0mg for about 125.0mg, the content of silver arrives about 0.50mg for about 0.10mg, the content of zinc arrives about 20.0mg for about 10.0mg, the content of chromium arrives about 0.20mg for about 0.05mg, and the content of orotic acid arrives about 500.0mg for about 150.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is that about 100.0mg is to about 300.0mg.
3. the therapeutic composition described in the claim 1, wherein, the about 10.0mg of the content of allocryptopine, the content of nimodipine is about 100.0mg, the content of potassium iodide is about 560.0mg, the content of potassium iodate is about 140.0mg, and the content of inuline is about 375.0mg, and the content of silver is about 0.50mg, the content of zinc is about 20.0mg, the content of chromium is about 0.20mg, the about 500.0mg of the content of orotic acid, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is about 300.0mg.
4. the therapeutic composition described in the claim 1, wherein, the content of allocryptopine is about 4.5mg, and the content of nimodipine is about 60.0mg, the content of potassium iodide is about 340.0mg, the content of potassium iodate is about 85.0mg, and the content of inuline is about 250.0mg, and the content of silver is about 0.30mg, the content of zinc is about 15.0mg, the content of chromium is about 0.125mg, and the content of orotic acid is about 325.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is about 200.0mg.
5. the therapeutic composition described in the claim 1, wherein, the content of allocryptopine is about 1.0mg, and the content of nimodipine is about 20.0mg, the content of potassium iodide is about 120.0mg, the content of potassium iodate is about 30.0mg, and the content of inuline is about 125.0mg, and the content of silver is about 0.10mg, the content of zinc is about 10.0mg, the content of chromium is about 0.05mg, and the content of orotic acid is about 250.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is about 100.0mg.
6. the described therapeutic composition of claim 1, it further comprises weight ratio, promptly, allocryptopine: nimodipine: potassium iodide: potassium iodate: inuline: silver: zinc: chromium: orotic acid: 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane was respectively about 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250: 100.
7. the described therapeutic composition of claim 1, wherein said compositions has a kind of form of the patient's of being suitable for medication, and described form can be from by selecting tablet, the tablet with coating, wafer, suppository, effervescent powder, the group that gel and colloid solution constituted.
8. therapeutic composition that is used for the treatment of the patient HIV that needs HIV treatment, this therapeutic composition comprises allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane, taraxasterol and the B-sitosterol with knock-down.
9. the described therapeutic composition of claim 8, wherein the content of allocryptopine arrives about 10.0mg for about 1.0mg, the content of nimodipine arrives about 100.0mg for about 20.0mg, the content of potassium iodide arrives about 560.0mg for about 120.0mg, the content of potassium iodate arrives about 140.0mg for about 30.0mg, the content of inuline arrives about 375.0mg for about 125.0mg, the content of silver arrives about 0.50mg for about 0.10mg, the content of zinc arrives about 20.0mg for about 10.0mg, the content of chromium arrives about 0.20mg for about 0.05mg, the content of orotic acid arrives about 500.0mg for about 150.0mg, the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane arrives about 300.0mg for about 100.0mg, the content of taraxasterol arrives about 400mg for about 250mg, and the content of B-sitosterol arrives about 500mg for about 300mg.
10. the therapeutic composition described in the claim 8, wherein the content of allocryptopine is about 10.0mg, the content of nimodipine is about 100.0mg, the content of potassium iodide is about 560.0mg, the content of potassium iodate is about 140.0mg, the content of inuline is about 375.0mg, the content of silver is about 0.50mg, the about 20.0mg of the content of zinc, the content of chromium is about 0.20mg, and the content of orotic acid is about 500.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is about 300.0mg, the content of taraxasterol is about 400mg, and the content of B-sitosterol is about 500mg.
11. the therapeutic composition described in the claim 8, wherein the content of allocryptopine is about 4.5mg, the content of nimodipine is about 60.0mg, the content of potassium iodide is about 340.0mg, the content of potassium iodate is about 85.0mg, the content of inuline is about 250.0mg, the content of silver is about 0.30mg, the content of zinc is about 15.0mg, the content of chromium is about 0.125mg, and the content of orotic acid is about 325.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is about 200.0mg, the content of taraxasterol is about 350mg, and the content of B-sitosterol is about 400mg.
12. the therapeutic composition described in the claim 8, wherein the content of allocryptopine is about 1.0mg, the content of nimodipine is about 20.0mg, the content of potassium iodide is about 120.0mg, the content of potassium iodate is about 30.0mg, the content of inuline is about 125.0mg, the content of silver is about 0.10mg, the content of zinc is about 10.0mg, the content of chromium is about 0.05mg, and the content of orotic acid is about 250.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is about 100.0mg, the content of taraxasterol is about 250mg, and the content of B-sitosterol is about 300mg.
13. a method for preparing the medicinal mixture that stops the HIV virus replication, this method comprises that allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, the 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane that will have knock-down mix to obtain a kind of medicinal mixture of the HIV of prevention virus replication together.
14. the method described in the claim 13, wherein said blend step is at room temperature finished.
15. the method described in the claim 13, wherein the content of allocryptopine arrives about 10.0mg for about 1.0mg, the content of nimodipine arrives about 100.0mg for about 20.0mg, the content of potassium iodide arrives about 560.0mg for about 120.0mg, the content of potassium iodate arrives about 140.0mg for about 30.0mg, the content of inuline arrives about 375.0mg for about 125.0mg, the content of silver arrives about 0.50mg for about 0.10mg, the content of zinc arrives about 20.0mg for about 10.0mg, the content of chromium arrives about 0.20mg for about 0.05mg, the content of orotic acid arrives about 500.0mg for about 150.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane arrives about 300.0mg for about 100.0mg.
16. the method described in the claim 13, wherein the content of allocryptopine is about 10.0mg, the content of nimodipine is about 100.0mg, and the content of potassium iodide is about 560.0mg, and the content of potassium iodate is about 140.0mg, the content of inuline is about 375.0mg, the content of silver is about 0.50mg, the about 20.0mg of the content of zinc, and the content of chromium is about 0.20mg, the content of orotic acid is about 500.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is about 300.0mg.
17. the method described in the claim 13, wherein be about 4.5mg, the content of nimodipine is about 60.0mg, and the content of potassium iodide is about 340.0mg, and the content of potassium iodate is about 85.0mg, the content of inuline is about 250.0mg, the content of silver is about 0.30mg, and the content of zinc is about 15.0mg, and the content of chromium is about 0.125mg, the content of orotic acid is about 325.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is about 200.0mg.
18. the method described in the claim 13, wherein the content of allocryptopine is about 1.0mg, the content of nimodipine is about 20.0mg, and the content of potassium iodide is about 120.0mg, and the content of potassium iodate is about 30.0mg, the content of inuline is about 125.0mg, the content of silver is about 0.10mg, and the content of zinc is about 10.0mg, and the content of chromium is about 0.05mg, the content of orotic acid is about 250.0mg, and the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane is about 100.0mg.
19. the described method of claim 13, wherein said medicinal mixture has comprised a kind of weight ratio, promptly, allocryptopine: nimodipine: potassium iodide: potassium iodate: inuline: silver: zinc: chromium: orotic acid: 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane was respectively 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250: 100.
20. the described method of claim 13, it further comprises the form that described medicinal mixture is converted into a kind of patient's of being suitable for medication, and described form can be from by selecting tablet, the tablet with coating, wafer, suppository, effervescent powder, the group that gel and colloid solution constituted.
21. treat the method that HIV infects for one kind, this method comprises that the patient to needing the HIV treatment uses a kind of medicinal mixture, and this medicinal mixture comprises allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, the 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane with knock-down.
22. the method described in the claim 21, wherein said medicinal mixture are to use by muscle.
23. the method described in the claim 21, wherein said medicinal mixture are to use by intravenous injection.
24. a method for preparing the medicinal mixture that stops the HIV virus replication, this method comprises that allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane, taraxasterol and the B-sitosterol that will have knock-down mix to obtain a kind of medicinal mixture of the HIV of prevention virus replication together.
25. the method described in claims 24, wherein said blend step is at room temperature finished.
26. the described method of claim 26, wherein the content of allocryptopine arrives about 10.0mg for about 1.0mg, the content of nimodipine arrives about 100.0mg for about 20.0mg, the content of potassium iodide arrives about 560.0mg for about 120.0mg, the content of potassium iodate arrives about 140.0mg for about 30.0mg, the content of inuline arrives about 375.0mg for about 125.0mg, the content of silver arrives about 0.50mg for about 0.10mg, the content of zinc arrives about 20.0mg for about 10.0mg, the content of chromium arrives about 0.20mg for about 0.05mg, the content of orotic acid arrives about 500.0mg for about 150.0mg, the content of 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane arrives about 300.0mg for about 100.0mg, the content of taraxasterol arrives about 400mg for about 250mg, and the content of B-sitosterol arrives about 500mg for about 300mg.
27. the described method of claim 13, wherein said medicinal mixture comprises a kind of weight ratio, promptly, allocryptopine: nimodipine: potassium iodide: potassium iodate: inuline: silver: zinc: chromium: orotic acid: 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane: taraxasterol: the B-sitosterol was respectively 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250: 100: 250: 300.
28. the described method of claim 28, it further comprises the form that described medicinal mixture is converted into a kind of patient's of being suitable for medication, and described form can be from by selecting tablet, the tablet with coating, wafer, suppository, effervescent powder, the group that gel and colloid solution constituted.
29. treat the method that HIV infects for one kind, this method comprises that the patient to needing the HIV treatment uses a kind of medicinal mixture, and this pharmaceutical mixture comprises allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane, taraxasterol and the B-sitosterol with knock-down.
30. the described method of claim 29, wherein said medicinal mixture are to use by muscle.
31. the described method of claim 29, wherein said medicinal mixture are to use by intravenous injection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/353,483 | 2003-01-29 | ||
| US10/353,483 US20030203045A1 (en) | 2002-04-30 | 2003-01-29 | Therapeutic composition for the treatment of HIV-1 and HIV-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1747726A true CN1747726A (en) | 2006-03-15 |
Family
ID=32823743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004800039434A Pending CN1747726A (en) | 2003-01-29 | 2004-01-29 | A therapeutic composition for the treatment of hiv-1 and hiv-2 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1589961A4 (en) |
| JP (1) | JP2006516633A (en) |
| KR (1) | KR20050094461A (en) |
| CN (1) | CN1747726A (en) |
| AU (1) | AU2004206996A1 (en) |
| CA (1) | CA2514252A1 (en) |
| RU (1) | RU2005123957A (en) |
| WO (1) | WO2004066954A2 (en) |
| ZA (1) | ZA200505977B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810625A (en) * | 2010-04-09 | 2010-08-25 | 上海新康制药厂 | Application of taraxasterol |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021161045A (en) * | 2020-03-31 | 2021-10-11 | 株式会社古川リサーチオフィス | Zinc compound mixed composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970212A (en) * | 1982-05-18 | 1990-11-13 | Nowicky Wassili | Method of treating human illnesses which compromise the ability to mount an effective immunological response |
| CA1337047C (en) * | 1988-08-18 | 1995-09-19 | Peter Dodd Cooper | Gamma inulin compositions |
| JP3479532B2 (en) * | 1989-03-31 | 2003-12-15 | ザ・チルドレンズ・メディカル・センター・コーポレーション | Treatment of AIDS dementia, spinal cord disorders and blindness |
| US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
| RU2107502C1 (en) * | 1997-03-27 | 1998-03-27 | Открытое акционерное общество "Ветеринарные препараты" | Iodine monochloride, veterinary preparation possessing wide range of action |
| WO2001000194A2 (en) * | 1999-06-29 | 2001-01-04 | Jacobs Robert H | A method for optimizing immune activity in the treatment of auto-immune diseases and chronic immune conditions |
| RU2195277C2 (en) * | 2001-02-09 | 2002-12-27 | Третьяков Василий Васильевич | Method of treatment of hiv-infection |
| GB2374008B (en) * | 2001-04-04 | 2005-03-16 | John Carter | Pharmaceutical compositions comprising copper and zinc |
| PL353693A1 (en) * | 2002-04-30 | 2003-11-03 | Bogusław Jeleń | Compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd4+ cells of human immunological system at all stages of infection and in the aids syndrome as well as method of manufacture of compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd+ cells of human immunological system at all stages of infection and in the aids syndrome |
-
2004
- 2004-01-29 KR KR1020057013692A patent/KR20050094461A/en not_active Application Discontinuation
- 2004-01-29 RU RU2005123957/15A patent/RU2005123957A/en not_active Application Discontinuation
- 2004-01-29 JP JP2006503151A patent/JP2006516633A/en active Pending
- 2004-01-29 CN CNA2004800039434A patent/CN1747726A/en active Pending
- 2004-01-29 EP EP04706521A patent/EP1589961A4/en not_active Withdrawn
- 2004-01-29 AU AU2004206996A patent/AU2004206996A1/en not_active Abandoned
- 2004-01-29 WO PCT/US2004/002536 patent/WO2004066954A2/en not_active Application Discontinuation
- 2004-01-29 CA CA002514252A patent/CA2514252A1/en not_active Abandoned
-
2005
- 2005-07-26 ZA ZA200505977A patent/ZA200505977B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810625A (en) * | 2010-04-09 | 2010-08-25 | 上海新康制药厂 | Application of taraxasterol |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2514252A1 (en) | 2004-08-12 |
| AU2004206996A1 (en) | 2004-08-12 |
| RU2005123957A (en) | 2006-01-27 |
| KR20050094461A (en) | 2005-09-27 |
| EP1589961A4 (en) | 2006-02-15 |
| ZA200505977B (en) | 2006-05-31 |
| EP1589961A2 (en) | 2005-11-02 |
| WO2004066954A3 (en) | 2005-03-17 |
| WO2004066954A2 (en) | 2004-08-12 |
| JP2006516633A (en) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1686117A (en) | Application of levoornidazole in preparation of anti anaerobic bacteria infection medicine | |
| CN1091635A (en) | As the 2-amino-6-n-pro-pyl-amino-4,5,6 with anti-strongly fragrant drugs with function, the 7-tetrahydro benzothiazol is used | |
| CN1198599C (en) | Long time drug-sustained release preparation | |
| CN1429558A (en) | Mannosan peptide injection and its preparation and use method | |
| CN1747726A (en) | A therapeutic composition for the treatment of hiv-1 and hiv-2 | |
| CN1956717A (en) | Niacin sustained release composition for oral administration | |
| CN1830440A (en) | Metronidazule injection and its preparation method and use | |
| CN1238054C (en) | Biotechnological formulation for suppressing and killing helicobacter pylori, its preparation and use | |
| CN101049337A (en) | Medication for curing furuncle, sore, and carbuncle, and preparation method | |
| CN1414847A (en) | Sustained-releasing antihelmintic compositions comprising praziquantel | |
| CN1206000C (en) | Sustained release implant, methods for preparation thereof and for treating cancer | |
| CN1864666A (en) | Lyophilized powder injection of levofloxacin mesylate and preparation method thereof | |
| CN112569358B (en) | Application of peinterferon and proto-oncogene product targeted inhibitor in synergistic inhibition of tumors | |
| CN1319533C (en) | Cefetamet pivoxil hydrochloride dispersion dispersion tablets and preparation method | |
| CN1170523C (en) | Sustained-release drug formulations for implantation | |
| CN1296050C (en) | Acarbose enteric coated tablets and its prepn. method | |
| CN1176655C (en) | Refapentine or rifampin liposome perfusate, injection and preparation process thereof | |
| CN101607080A (en) | Oral drugs of treatment diabetes and preparation method thereof | |
| CN1827117A (en) | Sustained release medicament of compound gossypol acetate | |
| CN1027959C (en) | Zn-Ca oral liquid and its preparing method | |
| CN1660141A (en) | Drop pills of arenobufagin and preparation method | |
| CN1268342C (en) | Medicine composition | |
| CN1278676C (en) | Curcumin injection and method for preparing the same | |
| CN1215831C (en) | Chinese medicine cataplasm matrix and preparing technique thereof | |
| CN1611218A (en) | Fixed dose compound preparation of antitubercular drug and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |